Supernus Pharmaceuticals (NASDAQ:SUPN) Director Frederick Hudson Sells 5,369 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Frederick Hudson sold 5,369 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the transaction, the director directly owned 60,413 shares of the company’s stock, valued at $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.30 on Monday, reaching $50.21. 517,222 shares of the company were exchanged, compared to its average volume of 762,366. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -73.84, a P/E/G ratio of 1.55 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company’s 50-day moving average is $51.22 and its two-hundred day moving average is $49.10.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Supernus Pharmaceuticals by 8.8% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after buying an additional 1,161 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Supernus Pharmaceuticals by 30.4% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after acquiring an additional 19,949 shares during the period. Ruffer LLP bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $2,647,000. Systematic Financial Management LP boosted its holdings in shares of Supernus Pharmaceuticals by 47.5% in the second quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock valued at $7,740,000 after acquiring an additional 79,041 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $1,301,000.

Wall Street Analyst Weigh In

SUPN has been the topic of several analyst reports. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Stifel Nicolaus raised their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.